Literature DB >> 27118126

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine.

Giorgio Treglia1, Cumali Aktolun2, Arturo Chiti3,4, Savvas Frangos5, Luca Giovanella6, Martha Hoffmann7, Ioannis Iakovou8, Jasna Mihailovic9, Bernd J Krause10, Werner Langsteger11, Frederik A Verburg12, Markus Luster13.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27118126     DOI： 10.1007/s00259-016-3404-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  30 in total

1.  Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.

Authors:  Niraj Naswa; Punit Sharma; Sudhir Suman Kc; Sneh Lata; Rakesh Kumar; Arun Malhotra; Chandrasekhar Bal
Journal:  Nucl Med Commun       Date:  2012-07       Impact factor: 1.690

2.  The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma.

Authors:  Trond Velde Bogsrud; Dimitrios Karantanis; Mark A Nathan; Brian P Mullan; Gregory A Wiseman; Jan L Kasperbauer; Carl C Reading; Trine Björo; Ian D Hay; Val J Lowe
Journal:  Mol Imaging Biol       Date:  2009-12-01       Impact factor: 3.488

3.  Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.

Authors:  Tatjana Traub-Weidinger; Daniel Putzer; Elisabeth von Guggenberg; Georg Dobrozemsky; Bernhard Nilica; Dorota Kendler; Reto Bale; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-15       Impact factor: 9.236

Review 4.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

5.  Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer.

Authors:  Michaël Soussan; Valérie Nataf; Khaldoun Kerrou; Dany Grahek; Odile Pascal; Jean-Noël Talbot; Françoise Montravers
Journal:  Nucl Med Commun       Date:  2012-07       Impact factor: 1.690

6.  Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.

Authors:  M Papotti; U Kumar; M Volante; C Pecchioni; Y C Patel
Journal:  Clin Endocrinol (Oxf)       Date:  2001-05       Impact factor: 3.478

7.  Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.

Authors:  Kathryn Tran; Sairah Khan; Mina Taghizadehasl; Fausto Palazzo; Andrea Frilling; Jeannie F Todd; Adil Al-Nahhas
Journal:  Hell J Nucl Med       Date:  2015-02-13       Impact factor: 1.102

Review 8.  Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues.

Authors:  Ali Salavati; Ameya Puranik; Harshad R Kulkarni; Hendra Budiawan; Richard P Baum
Journal:  Semin Nucl Med       Date:  2016-05       Impact factor: 4.446

Review 9.  Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.

Authors:  Håkan Geijer; Lars H Breimer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-20       Impact factor: 9.236

10.  (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.

Authors:  Aurélien Archier; Céline Heimburger; Carole Guerin; Isabelle Morange; Fausto F Palazzo; Jean-François Henry; Olivier Schneegans; Olivier Mundler; Ahmad Esmaeel Abdullah; Frédéric Sebag; Alessio Imperiale; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-24       Impact factor: 9.236
View more
  10 in total

1.  SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

Authors:  Anna Margherita Maffione; Francesco Giammarile; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-22       Impact factor: 9.236

2.  EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.

Authors:  Luca Giovanella; Giorgio Treglia; Ioannis Iakovou; Jasna Mihailovic; Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-04       Impact factor: 9.236

3.  18F-Fluoride (18F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines!

Authors:  Giorgio Treglia; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03       Impact factor: 9.236

Review 4.  Novel PET tracers: added value for endocrine disorders.

Authors:  Sébastien Bergeret; Judith Charbit; Catherine Ansquer; Géraldine Bera; Philippe Chanson; Charlotte Lussey-Lepoutre
Journal:  Endocrine       Date:  2019-03-14       Impact factor: 3.633

Review 5.  Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives.

Authors:  Michele Klain; Julien Hadoux; Carmela Nappi; Monica Finessi; Raffaele Ambrosio; Martin Schlumberger; Alberto Cuocolo; Désirée Deandreis; Domenico Salvatore
Journal:  Endocrine       Date:  2021-11-08       Impact factor: 3.633

6.  Bone and Calcified Soft Tissue Metastases of Medullary Thyroid Carcinoma Better Characterized on 18F-Fluoride PET/CT than on 68Ga-Dotatate PET/CT.

Authors:  Paulo Schiavom Duarte; Luciana Audi de Castroneves; Heitor Naoki Sado; Marcelo Tatit Sapienza; Ana Amélia Fialho de Oliveira Hoff; Carlos Alberto Buchpiguel
Journal:  Nucl Med Mol Imaging       Date:  2018-06-04

Review 7.  Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.

Authors:  Melpomeni Fani; Petra Kolenc Peitl; Irina Velikyan
Journal:  Pharmaceuticals (Basel)       Date:  2017-03-15

Review 8.  Medullary Thyroid Carcinoma: An Update on Imaging.

Authors:  Sergiy V Kushchayev; Yevgeniya S Kushchayeva; Sri Harsha Tella; Tetiana Glushko; Karel Pacak; Oleg M Teytelboym
Journal:  J Thyroid Res       Date:  2019-07-07

Review 9.  Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.

Authors:  Elisabeth von Guggenberg; Petra Kolenc; Christof Rottenburger; Renata Mikołajczak; Alicja Hubalewska-Dydejczyk
Journal:  Cancers (Basel)       Date:  2021-11-18       Impact factor: 6.575

10.  Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer.

Authors:  Evert F S van Velsen; Merel T Stegenga; Folkert J van Kemenade; Boen L R Kam; Tessa M van Ginhoven; W Edward Visser; Robin P Peeters
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.